Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20230 -130
- GSK Investigational Site
-
Rio de Janeiro, Brazil, 20211-030
- GSK Investigational Site
-
-
Bahía
-
Salvador, Bahía, Brazil, 41253-190
- GSK Investigational Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30130-100
- GSK Investigational Site
-
-
-
-
-
Koebenhavn Oe, Denmark, 2100
- GSK Investigational Site
-
Odense C, Denmark, 5000
- GSK Investigational Site
-
-
-
-
-
Bayonne cedex, France, 64109
- GSK Investigational Site
-
Besançon cedex, France, 25030
- GSK Investigational Site
-
Bobigny Cedex, France, 93009
- GSK Investigational Site
-
Caen cedex 9, France, 14033
- GSK Investigational Site
-
Marseille cedex 9, France, 13273
- GSK Investigational Site
-
Paris Cedex 12, France, 75571
- GSK Investigational Site
-
Toulouse, France, 31059
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 12200
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Stuttgart, Baden-Wuerttemberg, Germany, 70199
- GSK Investigational Site
-
Ulm, Baden-Wuerttemberg, Germany, 89081
- GSK Investigational Site
-
-
Bayern
-
Muenchen, Bayern, Germany, 81675
- GSK Investigational Site
-
-
Niedersachsen
-
Goettingen, Niedersachsen, Germany, 37075
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Duesseldorf, Nordrhein-Westfalen, Germany, 40225
- GSK Investigational Site
-
Duisburg, Nordrhein-Westfalen, Germany, 47166
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 50937
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- GSK Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- GSK Investigational Site
-
Shatin, New Territories, Hong Kong
- GSK Investigational Site
-
-
-
-
Calabria
-
Reggio Calabria, Calabria, Italy, 89100
- GSK Investigational Site
-
-
Toscana
-
Firenze, Toscana, Italy, 50134
- GSK Investigational Site
-
-
Veneto
-
Vicenza, Veneto, Italy, 36100
- GSK Investigational Site
-
-
-
-
-
Seoul, Korea, Republic of, 138-736
- GSK Investigational Site
-
Seoul, Korea, Republic of, 137-701
- GSK Investigational Site
-
Seoul, Korea, Republic of, 135-710
- GSK Investigational Site
-
-
-
-
-
San Juan, Puerto Rico, 00927
- GSK Investigational Site
-
-
-
-
-
Changhua, Taiwan, 500
- GSK Investigational Site
-
Taichung, Taiwan, 404
- GSK Investigational Site
-
Taipei, Taiwan, 100
- GSK Investigational Site
-
Taipei, Taiwan, 112
- GSK Investigational Site
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- GSK Investigational Site
-
Glasgow, United Kingdom, G12 0YN
- GSK Investigational Site
-
Leeds, United Kingdom, LS9 7TF
- GSK Investigational Site
-
London, United Kingdom, SE5 9RS
- GSK Investigational Site
-
London, United Kingdom, SW17 0RE
- GSK Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- GSK Investigational Site
-
-
California
-
Santa Monica, California, United States, 90404
- GSK Investigational Site
-
Stanford, California, United States, 94305
- GSK Investigational Site
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- GSK Investigational Site
-
Lake Worth, Florida, United States, 33467
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30341
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- GSK Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- GSK Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- GSK Investigational Site
-
Saint Louis, Missouri, United States, 63110
- GSK Investigational Site
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- GSK Investigational Site
-
-
New York
-
The Bronx, New York, United States, 10461
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- GSK Investigational Site
-
Philadelphia, Pennsylvania, United States, 19106
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15224
- GSK Investigational Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29601
- GSK Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- GSK Investigational Site
-
New Braunfels, Texas, United States, 78130
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22205
- GSK Investigational Site
-
Fairfax, Virginia, United States, 22031
- GSK Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult subjects (18 years of age or older) with advanced MDS, sAML/MDS, or de novo AML with >=10% and <=50% blasts in bone marrow. Peripheral blood blast change over time should not be suggestive of highly proliferative disease (as judged by the investigator).
- Subjects must be dependent on regular platelet transfusions or have a platelet count taken within the 4 weeks prior to randomization that is <30 Gi/L.
- Subjects must be relapsed, refractory or ineligible to receive standard treatment options of azacitidine and decitabine and must be relapsed, refractory or ineligible to receive intensive chemotherapy or autologous/allogeneic stem cell transplantation. A subject may be considered relapsed/refractory to a standard treatment if it is discontinued due to lack of efficacy. For subjects ineligible for standard treatments, it is permissible to start one of these standard treatments while on study medication if the Investigator considers that the subject becomes eligible during the course of the study.
- Prior therapy with demethylating agents (azacitidine or decitabine), lenalidomide or IL-11(oprelvekin) must have been completed at least 4 weeks before Day 1; antithymocyte/antilymphocyte globulin, intensive chemotherapy, or autologous/allogeneic stem cell transplantation must have been completed at least 2 months before Day 1. If a subject must discontinue a course of therapy due to lack of efficacy, the washout periods listed above do not apply (and the patient may be screened and randomized immediately if other eligibility criteria are met).
- Subjects must have platelet count and platelet transfusion data available over a period of 4 weeks prior to randomization.
- Subjects with advanced MDS, sAML/MDS, or de novo AML must have stable disease indicated by a doubling time of peripheral blast counts >7 days during screening.
- During the 4 weeks prior to randomization, subjects must have a baseline bone marrow examination including the following:
- cytomorphology to confirm bone marrow blasts between 10-50%,
- cytogenetics (provide only most prevalent abnormal clone),
The results of the above tests are required prior to subject randomization.
- Supportive/palliative therapies such as cytokines (except for IL-11; oprelvekin), valproic acid, all-trans retinoic acid or mild chemotherapy are allowed if part of the local SOC, provided those therapies have been at a stable dose for 4 weeks. If the subject chooses to discontinue these therapies prior to study entry, they must be completed 4 weeks prior to enrollment into this study, unless the therapy is discontinued due to lack of efficacy. Erythropoiesis-stimulating agents (ESAs) in anemic subjects or granulocyte colony-stimulating factor (G-CSF) in subjects with severe neutropenia and recurrent infections are allowed during the study as per accepted standards. Subjects who enter the study on ESAs or G-CSF should continue at the same dose schedule until the optimal dose of study medication has been established.
- ECOG Status 0-3.
- Subject is able to understand and comply with protocol requirements and instructions.
- Subject has signed and dated informed consent.
- Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) must be within 80 to 120% of the normal range at baseline.
- Adequate baseline organ function defined by the criteria below:
- total bilirubin (except for Gilbert's Syndrome) <= 1.5xULN
- ALT and AST <= 3xULN
- creatinine <= 2xULN
- albumin must not be below the lower limit of normal (LLN) by more than 20%.
- Subject is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must either be of non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or post-menopausal >1 year), or of childbearing potential and use 1 of the following highly effective methods of contraception (i.e., Pearl Index <1.0%) from 2 weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
- Complete abstinence from intercourse;
- Intrauterine device (IUD);
- Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
- Male partner is sterile prior to entry into the study and is the only partner of the female;
- Systemic contraceptives (combined or progesterone only).
Exclusion Criteria:
- Subjects with a diagnosis of acute promyelocytic leukemia.
- History of treatment for cancer (other than MDS, sAML/MDS, or de novo AML) with systemic chemotherapy and/or radiotherapy within the last 2 years.
- History of treatment with romiplostim or other TPO-R agonists.
- Pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc >450 msec (QTc >480 msec for subjects with Bundle Branch Block).
- Bone marrow fibrosis that leads to an inability to aspirate marrow for assessment.
- Spleen size >14 cm (length as per ultrasound examination).
- Leukocytosis >=25,000/uL prior to Day 1 of study medication.
- Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test) at screening or pre-dose on Day 1.
- Current alcohol or drug abuse.
- Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
- Active and uncontrolled infections.
- Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).
- Subjects with liver cirrhosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Placebo tablets with no active pharmaceutical ingredient
|
|
ACTIVE_COMPARATOR: Eltrombopag
|
thrombopoietin receptor agonist
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability parameters including non-hematological laboratory Grade 3/Grade 4 toxicities, change in bone marrow blast counts from baseline and adverse events reporting.
Time Frame: Approximately 46 months
|
Approximately 46 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects with a baseline platelet count <20 Gi/L and an increase to >20 Gi/L and by at least 2x baseline; or a baseline platelet count between >=20-<30 Gi/L and an absolute platelet count increase to >=50 Gi/L at any time during treatment.
Time Frame: Approx. 46 months
|
Approx. 46 months
|
|
Frequency and number of units of platelet transfusions during the treatment and follow-up periods for eltrombopag- and placebo-treated subjects.
Time Frame: approx 46 months
|
approx 46 months
|
|
The incidence and severity of bleeding events, measured using the World Health Organization (WHO) Bleeding Scale, during the treatment and 4 week follow-up periods for eltrombopag- and placebo-treated subjects.
Time Frame: approx. 46 months
|
approx. 46 months
|
|
Overall survival (OS) of eltrombopag- and placebo-treated subjects.
Time Frame: approx. 46 months
|
approx. 46 months
|
|
Change in health-related quality of life as measured using the EQ-5D questionnaire.
Time Frame: approx. 46 months
|
approx. 46 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011 Mar;35(3):323-8. doi: 10.1016/j.leukres.2010.06.029. Epub 2010 Aug 4.
- Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Gotze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 112509
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.